Selected prospective studies of Burkitt lymphoma in adults.
| Citation . | Regimen . | N . | Median age* . | 2-year survival . |
|---|---|---|---|---|
| Hoelzer B-NHL83 (1996)22 | Short duration/dose intensive; pediatric NHL based | 24 | 33 | 49% (estimated) |
| Hoelzer B-NHL86 (1996)22 | Short duration/dose intensive; pediatric NHL based | 35 | 36 | 51% (estimated) |
| Magrath (1996)18 | CODOX-M/IVAC | 54 | 24 | 89% (actual) |
| Thomas (1999)25 | Hyper-CVAD | 48 | 58 | 39% (estimated) |
| Mead (2002)20 | Modified CODOX-M/IVAC | 52 | 26.5 | 70% (estimated) |
| Rizzieri (2004)21 | Short duration/dose intensive | 92 | 47 | Cohort 1: 54% (estimated); Cohort 2: 50% (estimated) |
| Lacasce (2004)19 | Modified CODOX-M/IVAC | 14 | 47 | 71% (estimated) |
| Van Imhoff (2005)23 | Short duration/dose intensive; ASCT | 27 | 36 | 81% (estimated) |
| Thomas (2006)26 | Hyper-CVAD with rituximab | 31 | 46 | 89% (estimated) |
| Kujawski (2007)27 | Short duration/dose intensive | 10 | 51 | 72% (estimated) |
| Citation . | Regimen . | N . | Median age* . | 2-year survival . |
|---|---|---|---|---|
| Hoelzer B-NHL83 (1996)22 | Short duration/dose intensive; pediatric NHL based | 24 | 33 | 49% (estimated) |
| Hoelzer B-NHL86 (1996)22 | Short duration/dose intensive; pediatric NHL based | 35 | 36 | 51% (estimated) |
| Magrath (1996)18 | CODOX-M/IVAC | 54 | 24 | 89% (actual) |
| Thomas (1999)25 | Hyper-CVAD | 48 | 58 | 39% (estimated) |
| Mead (2002)20 | Modified CODOX-M/IVAC | 52 | 26.5 | 70% (estimated) |
| Rizzieri (2004)21 | Short duration/dose intensive | 92 | 47 | Cohort 1: 54% (estimated); Cohort 2: 50% (estimated) |
| Lacasce (2004)19 | Modified CODOX-M/IVAC | 14 | 47 | 71% (estimated) |
| Van Imhoff (2005)23 | Short duration/dose intensive; ASCT | 27 | 36 | 81% (estimated) |
| Thomas (2006)26 | Hyper-CVAD with rituximab | 31 | 46 | 89% (estimated) |
| Kujawski (2007)27 | Short duration/dose intensive | 10 | 51 | 72% (estimated) |